Table 2.
Characteristics of patients who did or did not develop secondary AML/MDS
| Pt. characteristics | No secondary MDS/AML (N = 38) |
Secondary MDS/AML (N = 5) |
|---|---|---|
| Median age (range) | 64 years (23-74) | 65 years (58-68) |
| No. of chemo regimens used before enrollment | ||
| 1 | 7 (18%) | 2 (40%) |
| ≥2 | 31 (82%) | 3 (60%) |
| Radiation/ radioimmunotherapy |
11 (29%) | 0 |
| Median CD 34 cell dose infused (range) |
3.1 (1.8-7.4) | 3.4 (2.1-8.5) |
| Median day of neut engraftment (range) |
11 (9-13) | 12 (11-13) |
| Median day of platelet engraftment (range) |
16 (11-77) | 19 (12-21) |
| Day 100 | ||
| Median WBCa (range) | 5 (1.3-11.5) | 3.5 (2.7-4.8) |
| Median Hbb (range) | 12 (9.6-14) | 12.8 (8.6-13.9) |
| Median plateleta (range) | 128 (62-287) | 73 (53-100) |
| 1 year | ||
| Median WBCa (range) | 4.9 (3-17.4) | 4.2 (3.4-16.8) |
| Median Hbb (range) | 12.3 (8.4-14.7) | 12.1 (10.3-12.3) |
| Median plateleta (range) | 137 (20-305) | 73 (57-107) |
Abbreviations: HD = Hodgkin disease, MM = multiple myeloma,NHL = Non-Hodgkin Lymphoma, VGPR = very good partial response,PR = Partial response, neut = neutrophil, Hb = hemoglobin. a×109/L. bg/dL.